Combination therapies and methods for myelination and treatment of age-related hearing loss
By combining drug compositions with audio files, myelin regeneration is promoted, addressing central hearing loss and cocktail party defects, achieving non-invasive therapeutic effects.
Patent Information
- Application Number
- CN202580027893.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2024-03-15
- Filing Date
- 2025-03-14
- Publication Date
- 2026-11-17
AI Technical Summary
Existing technologies are insufficient to effectively promote myelin regeneration, especially in the treatment of central hearing loss and cocktail party defects. Furthermore, conventional drug methods are invasive and risky, and there is a lack of effective combination therapies.
Combination therapy using drug combinations such as antihistamines and audio files promotes the regeneration and growth of neuronal myelin sheaths by administering drugs such as chlormastine in conjunction with specific audio stimulation.
It achieves non-invasive myelin regeneration, improves central hearing loss and cocktail party deficit, and enhances patients' spatial hearing ability and sound localization accuracy.
Smart Images

Figure CN123124973A_ABST
Abstract
Description
[0001] Government rights This invention was carried out with government support under license number R01 DC 017924 granted by the National Institute on Deafness and Other Communication Disorders of the National Institutes of Health (NIH). The government owns certain rights to this invention. Cross-references to related applications
[0002] This application claims the benefit and priority of U.S. Provisional Patent Application No. 63 / 566,148, filed March 15, 2024, the entire contents of which are incorporated herein by reference. Technical Field
[0003] The embodiments of this disclosure generally relate to combination therapies and methods for myelin growth and / or myelin regeneration. The embodiments described herein also relate to such combination therapies and methods for treating various diseases or medical conditions in patients, such as age-related hearing loss. Background Technology
[0004] Demyelination is involved in a variety of diseases and medical conditions, such as age-related hearing loss. Age-related hearing loss, also known as presbyopia, begins in middle age and affects approximately one-third of middle-aged adults and more than half of adults aged 70 and older. Age-related hearing loss can be associated with secondary medical conditions such as depression, dementia, or Alzheimer's disease, making early diagnosis and treatment of hearing loss crucial for healthy aging. Research on myelin regeneration is ongoing. Current advanced techniques for myelin regeneration include surgical cell implantation and drug-induced myelin repair. However, surgery is expensive and invasive. While conventional drugs used for myelin repair may have beneficial effects on myelination, these drugs are insufficient to promote myelin regeneration and sometimes carry high-risk characteristics. Furthermore, there is currently no cure or treatment for patients exhibiting cocktail party deficit.
[0005] New methods and combination therapies are needed for myelination. Methods and combination therapies are also needed for treating, for example, age-related hearing loss. Methods and combination therapies are also needed for treating cocktail party defects. Summary of the Invention
[0006] The embodiments of this disclosure generally relate to combination therapies and methods for myelin growth and / or myelin regeneration. The embodiments described herein also relate to such combination therapies and methods for treating various diseases or medical conditions in patients, such as age-related hearing loss. In some instances, the combination therapy includes a drug or pharmaceutical composition (e.g., clemastine fumarate) used in combination with an audio file. The patient takes or is administered the drug in any suitable dosage form, such as orally, intravenously, intramuscularly, subcutaneously, parenterally, spinally, or epidermally (e.g., by injection or infusion). The patient listens to or is directed to listen to the audio file. The inventors have found that the combination therapies and methods of this disclosure can be used for myelin regeneration and myelin regeneration. In addition to age-related hearing loss, the embodiments described herein can be used to treat various medical conditions, such as autism, exposure to environmental noise, and early childhood ear infections.
[0007] In one embodiment, a combination therapy is provided. The combination therapy includes a drug or a drug composition and an audio file. The combination therapy may be used to induce myelination in a patient, induce myelination in a patient, treat a patient with central hearing loss, treat a patient with cocktail party deficit, treat a patient with age-related hearing loss, treat a patient with autism, treat a patient with cocktail party deficit caused by, for example, a chronic ear infection in childhood or exposure to environmental noise, or a combination thereof.
[0008] In another embodiment, a method for inducing myelin growth in a patient is provided. The method includes administering the drug or pharmaceutical composition described herein to the patient and having the patient hear or listen to the audio file described herein.
[0009] In another embodiment, a method for regenerating the myelin sheath of a patient is provided. The method includes administering the drug or pharmaceutical composition described herein to the patient and having the patient hear or listen to the audio file described herein.
[0010] In another embodiment, a method for treating central hearing loss in a patient is provided. The method includes administering the medicament or pharmaceutical composition described herein to the patient and enabling the patient to hear or listen to the audio file described herein.
[0011] In another embodiment, a method for treating a patient's cocktail party defect is provided. The method includes administering the drug or pharmaceutical composition described herein to the patient and enabling the patient to hear or listen to the audio file described herein.
[0012] In another embodiment, a method for treating a patient's disease or medical condition is provided. The method includes administering the medicament or pharmaceutical composition described herein to the patient and enabling the patient to hear or listen to the audio file described herein. The disease or medical condition may include age-related hearing loss, autism, or cocktail party deficit due to chronic ear infection or exposure to environmental noise.
[0013] In another embodiment, a combination therapy is provided for stimulating myelin regeneration in neurons of a patient with hearing loss. The combination therapy includes a drug or pharmaceutical composition comprising an antihistamine, a myelin regeneration therapy, a prescription therapy for treating multiple sclerosis, or a combination thereof. The combination therapy also includes an audio file configured to promote myelin regeneration in neurons after administration of the drug or pharmaceutical composition.
[0014] In another embodiment, a method is provided for stimulating myelin regeneration in neurons of a patient with hearing loss. The method includes administering a drug or pharmaceutical composition to the patient, the drug or pharmaceutical composition comprising an antihistamine, a myelin regeneration therapy, a prescription therapy for treating multiple sclerosis, or a combination thereof. The method also includes having the patient hear or listen to an audio file configured to promote myelin regeneration in the neurons after administration of the drug or pharmaceutical composition.
[0015] In another embodiment, a combination therapy is provided for growing myelin sheaths on neurons in a patient with hearing loss. The combination therapy includes an antihistamine. The combination therapy also includes an audio file configured to promote myelin sheath growth on neurons after administration of the antihistamine. Attached Figure Description
[0016] To gain a more detailed understanding of the foregoing features of this disclosure, the brief overview of this disclosure can be described in more detail with reference to embodiments, some of which are illustrated in the accompanying drawings. However, it should be noted that the drawings illustrate exemplary embodiments only and should not be construed as limiting their scope, and may permit other equally effective embodiments.
[0017] Figure 1A This is a schematic diagram illustrating the connectivity along the sound localization pathway. Dashed arrows represent excitatory projections; solid arrows represent glycineric projections. Figure 1A In this context, "LSO" refers to the lateral superior olivary nucleus, "MSO" refers to the medial superior olivary nucleus, and "MNTB" refers to the medial trapezius nucleus.
[0018] Figure 1BAn explanation of how to measure PPI in gerbils is provided. PPI stands for Prepulse Inhibition and is a measure of an animal's ability to localize sounds, with higher numbers indicating better localization. A startle speaker is mounted on top of the animal, and this speaker is not one of the speakers in the illustrated array. The different shaded lines in the speaker arc at the top of the figure represent swaps in one experiment. In one trial, one hollow speaker is swapped with another; in different trials, a speaker filled with one shaded line is swapped with another, and so on. Below the animal in the figure is a hypothetical timeline along the x-axis: speaker 1 sounds first, then speaker 2, followed by the startle sound. All of this occurs within the same trial.
[0019] Figure 2A and 2B The study presents vocalization data from humans and gerbils, demonstrating that age-related declines in vocalization abilities or cocktail party performance are common in mammals. Figure 2A Human performance in spatial noise speech separation tasks declines with age. Figure 2B Young gerbils (circles and rectangles filled with forward slashes " / ") performed significantly better than older gerbils (hollow circles and rectangles) in the speaker switching task. The y-axis is plotted as PPI (pre-pulse suppression), which is calculated as (1 - startle during the test period / startle during the control period), so values close to zero indicate no speaker switching was detected, while positive values indicate that switching was detected.
[0020] Figures 3A-3C The study showed that a decrease in auditory brainstem response (ABR) wave III is a comorbidity of spatial hearing deficits in humans and gerbils. Figure 3A :like Figure 2A The human wave III amplitude shown in the data from many of the same listeners indicates that wave III decreases with age. Figure 3B Regardless of age, the decrease in wave III amplitude is particularly pronounced in individuals with spatial hearing impairment, further emphasizing the relationship between these wave III variations and spatial hearing difficulties. Figure 3C A similar age-related decline in wave III was observed in gerbils. These animals are also generally... Figure 2B The same group of animals discussed in the article.
[0021] Figure 3D The image shows a coherent anti-Stokes Raman spectroscopy (CARS) image in which the laser was tuned to the resonance frequency of the CH2 bond (792.2 nm) to image the vibrating CH2 bond.
[0022] Figure 4The image shows coherent anti-Stokes Raman spectroscopy (CARS) images and axon diameter data, which demonstrate the presence of afferent fiber bundles in the MNTB of older gerbils. Figure 1A Demyelination was observed in the bundles indicated by the asterisks next to the dashed arrows. The CARS samples included older gerbils (top right) and younger gerbils (top left). Measurements and quantifications of axon diameter (bottom) showed a small but highly significant difference in axon diameter between older and younger animals (p < 0.001).
[0023] Figure 5A The spatial discrimination ability of prepulse inhibition (PPI) is shown in control gerbils (shaded) and gerbils (without shaded) 1.5 and 3 weeks after lyso injection. The curves represent the mean PPI (center line), mean plus standard error (upper boundary of the clouded shading band), and mean minus standard error (lower boundary of the clouded shading band) of the entire tested animal population.
[0024] Figure 5B The unilateral ABR (left panel) and binaural interaction components (BIC, right panel) are shown before and 1–3 weeks after injection. BIC DN1 (the first negative peak of BIC) disappeared at 1 and 2 weeks after injection, but recovered by 3 weeks.
[0025] Figure 5C The effect of lyso injection on axonal diameter after injection was shown.
[0026] Figure 5D The CARS images show that the axon diameter of the spherical plexiform cells in the control group (left panel) was significantly larger than that in the lyso treatment group (one and two weeks after lyso injection). By three weeks post-injection, the axon diameter had returned to the control group level.
[0027] Figure 6 The data shown indicate that clomastine and sound therapy can salvage vocal localization in gerbils. Solid line = PPI performance of older gerbils before treatment. Dashed line = PPI performance of the same animals after one month of treatment under the following conditions (post-treatment): control solution and no sound (top left); control solution and sound (top right); clomastine solution and no sound (bottom left); clomastine solution and sound (bottom right). N = 3 to 5 animals per group.
[0028] Figure 7The data shown indicate that treatment with clomastine and sound can salvage components of ABR wave III and BIC. Top: Waveforms of animals before and after treatment with the control solution and without sound. Bottom: Waveforms of animals treated with clomastine and with sound. Note the increase in unilateral wave III and the sharpening of the DN1 wave in the BIC in the treated animals. In contrast, the control animals did not show such improvements; instead, the curves deteriorated further during the experimental timeline.
[0029] Figure 8 CARS imaging from the control / silent group (top left) and the clomastine / voiced group (top right) is shown. Quantitative analysis of all CARS data from this experiment (bottom) shows a significant increase in axonal thickness in the treatment group.
[0030] For ease of understanding, the same reference numerals have been used to denote common elements in the figures where possible. Elements and features of one embodiment may be advantageously incorporated in other embodiments without further elaboration. Detailed Implementation
[0031] The embodiments of this disclosure generally relate to combination therapies and methods for myelin growth and / or myelin regeneration. The embodiments described herein also relate to such combination therapies and methods for treating various diseases or medical conditions in patients, such as age-related hearing loss, autism, exposure to sound, or ear infections. The terms “patient,” “subject,” and “individual” are used interchangeably herein and refer to vertebrates, such as mammals. Mammals may include (but are not limited to) humans, non-human primates, rodents (e.g., rats, mice, or gerbils), and livestock (e.g., dogs and cats), as well as other animals. The compositions, combination therapies, methods, and treatments described herein are not limited to human diseases but are also applicable to other mammals, such as non-human primates, rodents (e.g., rats, mice, or gerbils), and livestock (e.g., dogs and cats), as well as other animals.
[0032] Regarding hearing loss, there are different types: central hearing loss and peripheral hearing loss. Central hearing loss is a type of hearing impairment caused by dysfunction of the central auditory processing system, which includes the auditory nerve and the auditory pathways in the brain. This type of hearing loss can be caused by a variety of factors, such as neurological disorders, brain injury, or degenerative diseases, and affects an individual's ability to interpret and understand sound. Central hearing loss is associated with central auditory processing disorder (CAPD). Peripheral hearing loss is a type of hearing impairment caused by dysfunction in the ear, such as loss of hair cells in the inner ear. While both central and peripheral hearing loss are important risk factors for physical and cognitive impairment, the embodiments described herein are for the treatment of central hearing loss. To date, there is no treatment for central hearing loss, while peripheral hearing loss can be treated with hearing aids, cochlear implants, or other devices.
[0033] The combination therapies and methods described in this article can be used to grow myelin sheaths or promote the regeneration of myelin sheaths in nerve cell axons. Myelin sheaths are lipid-rich substances that surround nerve cell axons. The role of myelin sheaths is to provide insulation for nerve cell axons and to increase the speed at which electrical impulses are conducted along the axon length. Demyelination refers to the loss or degradation of myelin sheaths and is involved in many neurodegenerative diseases, including age-related hearing loss and multiple sclerosis.
[0034] Research on myelin regeneration (i.e., repair of damaged myelin sheaths) is ongoing. Current advanced techniques for myelin regeneration include surgical cell implantation and drug-induced myelin repair. However, surgery is expensive and invasive. While conventional drugs used for myelin repair may have beneficial effects on myelination, they are insufficient to promote myelin regeneration, at least in cases of central hearing loss, and sometimes carry high-risk characteristics. Furthermore, there is currently no cure or treatment for cocktail party deficit. Patients with cocktail party deficit lack the ability to isolate stimuli. For example, cocktail party deficit manifests as difficulty understanding speech in situations with multiple speakers.
[0035] Unlike conventional techniques, the embodiments described herein are non-invasive and promote myelin regeneration. Furthermore, the embodiments described herein provide the first known treatment for patients exhibiting cocktail party defects.
[0036] Embodiments of this disclosure relate to combination therapies. Combination therapies include drugs or drug compositions. Combination therapies also include audio files.
[0037] The drug or pharmaceutical composition may include antihistamines such as chlormastine (e.g., chlormastine fumarate), GSK239512 (an orally administered centrally acting antihistamine), or combinations thereof. The drug or pharmaceutical composition may include prescription disease-modifying therapies and / or myelin regeneration therapies for the treatment of multiple sclerosis. These myelin regeneration therapies enhance the regenerative response through myelin repair. Myelin regeneration therapies include therapies that target the recruitment, differentiation, and survival of oligodendrocyte precursors, as well as therapies that overcome myelin regeneration inhibitors.
[0038] Medicines or pharmaceutical compositions used to treat multiple sclerosis and / or myelin regeneration may include (but are not limited to) the following: evobrutinib; SAR442168 (a Bruton's tyrosine kinase inhibitor in a phase 2 clinical trial); masitinib; imatinib; ibudilast; BIIB033 (An antibody against LINGO-1 containing leucine-rich repeat sequences and immunoglobulin-like domain protein 1, i.e., anti-LINGO-1 antibody); opicinumab (an antibody against LINGO-1); elezanumab; autologous hematopoietic stem cell transplantation (AHSCT); simvastatin; vitamin D3; biotin (e.g., MD1003, a high-dose biotin); lipoic acid; nanocrystalline gold; laquinimod; GNbAC1 mAb (a monoclonal antibody against human endogenous retroviral envelope protein); IMU-838 (vidofludimus calcium); erythropoietin α; pioglitazone; montelukast; hydroxychloroquine; losartan; SPARC1103 (a GABA...) BRetinyl receptor agonists); Amantadine; Modanafil; Methylphenidate; BX-1 (dronabinol); ADS-5102 (amantadine extended-release); Arbaclofen (the R enantiomer of baclofen); Insulin; Intranasal insulin; Adderall; Adderall extended-release; GSK239512 (an orally administered centrally penetrating antihistamine); Ocrelizumab; Quetiapine (e.g., quetiapine fumarate); Domperidone; Antisemaphorin 4D (e.g., humanized anti-Sema4D monoclonal antibody VX15 / 2503); IRX4204 (a retinoic acid receptor γ-ray agonist). (RXR-γ) agonists); κ opioid agonists (e.g., U-50488, CAS No.: 67198-13-4); sphingosine-1-phosphate (S1P) receptor modulators (e.g., fingolimod or siponimod); γ-secretase inhibitors (e.g., quecertin); teriflunomide; bexarotene; bazedoxifene; phenytoin; amiloride; adrenocorticotropic hormone; fluoxetine; and riluzole.
[0039] A combination of drugs (or drug compositions) may be used.
[0040] The actual dose level of a drug or pharmaceutical composition can be altered to obtain an amount of active ingredient that effectively achieves the desired therapeutic response for a specific patient, composition, and administration mode, and is non-toxic to the patient. The selected dose level can depend on a variety of pharmacokinetic factors, including the activity of the specific composition used in this disclosure; the route of administration; the time of administration; the excretion rate of the specific compound used; the duration of treatment; other drugs, compounds, and / or materials used in combination with the specific composition used; the age, sex, weight, condition, general health status, and medical history of the patient being treated; and similar factors well known in the medical field.
[0041] Dosage can be described as a “pharmacologically effective amount” or a “therapeuticly effective amount.” The terms “pharmacologically effective amount” or “therapeuticly effective amount” refer to a non-toxic but sufficient quantity of an active agent (or a composition containing an active agent) to provide the desired level in the bloodstream of the patient to be treated or at the site of action (e.g., intracellularly), and / or to provide the desired physiological, biophysical, biochemical, pharmacological, or therapeutic response. The exact amount required will vary from patient to patient and will depend on a variety of factors, such as the active agent, the activity of the composition, the delivery device used, the physical characteristics of the composition, the intended patient use (e.g., the number of doses administered daily), and patient considerations such as the patient’s species, age and general condition, the severity of the condition being treated, any other medications the patient is taking, the mode of administration, etc. These factors and considerations can be determined by those skilled in the art. The appropriate “effective” amount for any individual case can be determined by those skilled in the art using routine experiments based on the information provided herein.
[0042] For example, a therapeutically effective amount of a drug or drug composition may refer to an amount of drug or drug composition that, in combination with an audio file heard or listened to, promotes myelin growth (or myelin regeneration) of neurons.
[0043] In some embodiments that can be combined with other embodiments, the dosage of the drug or drug composition for a 72 kg patient, in the case of chlormastine, may be from about 1 mg to about 40 mg.
[0044] Drugs or drug compositions may be formulated using pharmaceutically acceptable carriers or excipients, as well as any other suitable adjuvants and diluents, according to conventional techniques, such as those disclosed in Remington: The Science and Practice of Pharmacy, 19th edition, edited by Gennaro, Mack Publishing Co., Easton, Pa., 1995.
[0045] For the purposes of this disclosure, pharmaceutically acceptable carriers include any physiologically compatible suitable solvents, dispersion media, coatings, antimicrobial agents, antifungal agents, isotonic delay agents, and absorption delay agents. In some embodiments, the carrier may be suitable for intravenous, intramuscular, subcutaneous, parenteral, spinal, or epidermal administration (e.g., by injection or infusion). Depending on the route of administration, the active compound (e.g., a drug or pharmaceutical composition) may be coated in the material to protect the compound from acids and other natural conditions that may inactivate the compound.
[0046] Carriers or excipients used in pharmaceuticals or pharmaceutical compositions may include (but are not limited to) maleic acid, tartaric acid, lactic acid, citric acid, acetic acid, sodium bicarbonate, sodium phosphate, histidine, glycine, sodium chloride, potassium chloride, calcium chloride, zinc chloride, physiological saline, dimethyl sulfoxide (DMSO), water, dextran, N-methylpyrrolidone, N,N-dimethylacetamide, ethanol, propylene glycol, polyethylene glycol, diethylene glycol monoethyl ether, surfactant polyoxyethylene-sorbitan monooleate, or combinations thereof.
[0047] Audio files or sound files can be any suitable file or file type. Audio files can be audio tracks. Audio files can be encoded in any suitable format, such as digital formats like MP3. Audio files can be decoded by any suitable communication device, such as personal communication devices like smartphones, computers, dedicated players, players integrating other technologies, or combinations thereof. Audio files can be played as audio broadcasts via speakers, headphones (e.g., over-ear headphones, on-ear headphones, earbuds, or in-ear headphones) or other suitable audio projection devices.
[0048] Audio files may include a variety of audio components. Audio components may be rapidly changing in time. Audio components may include rapid transients having frequencies in the range of about 100 Hz to about 800 Hz, for example, about 200 Hz to about 600 Hz. Alternatively or additionally, audio components of an audio file may include rapidly changing components in time, including (but not limited to) binaural beats with a carrier frequency within the audible range of older human individuals (e.g., about 10 kHz or lower), amplitude-modulated signals containing a carrier frequency of about 10 kHz or lower and modulated according to frequencies between about 50 Hz and about 500 Hz, frequency-modulated signals with similar modulation parameters, rapid tapping, or combinations thereof.
[0049] Audio files can have any suitable sound intensity. The sound intensity of an audio file can be approximately 85 dB or lower, for example, in the range of approximately 10 dB to approximately 85 dB, for example, approximately 20 dB to approximately 80 dB, for example, approximately 30 dB to approximately 75 dB, for example, approximately 40 dB to approximately 70 dB, for example, approximately 50 dB to approximately 65 dB, or approximately 60 dB to approximately 85 dB, for example, approximately 70 dB to 80 dB, or approximately 75 dB to approximately 85 dB, or approximately 80 to approximately 85 dB, but other values may also be considered. Any of the foregoing figures may be used individually to describe an open range or in combination to describe a closed range.
[0050] The sound intensity of audio files is typically 85 dB or lower, because prolonged exposure to levels above 85 dB can lead to hearing loss (loss of hair cells at the inner ear level).
[0051] Audio files can have any suitable audio duration, such as from about 1 minute to about 10 hours, from about 5 minutes to about 6 hours, from about 10 minutes to about 5 hours, from about 15 minutes to about 4 hours, from about 30 minutes to about 3 hours, from about 45 minutes to about 1.5 hours, or about 1 hour, but other values may also be considered. Any of the foregoing figures may be used alone to describe an open range or in combination to describe a closed range.
[0052] The audio file can be a one-hour audio file in MP3 format, featuring rapid transients and combining multiple components that change rapidly over time, such as binaural beats, amplitude and frequency modulation signals, and rapid tapping.
[0053] Combination therapy can be used to treat a variety of medical conditions in patients, such as age-related hearing loss, autism, hearing damage caused by noise exposure or early childhood ear infections, etc.
[0054] Combination therapy can be used to promote myelination, myelinate formation, myelinate regeneration, treat central hearing loss, treat cocktail party defects, or a combination thereof.
[0055] Combination therapy can induce the flow of one or more afferent fibers to the medial trapezius nucleus (MNTB). Figure 1A Myelin growth (as indicated by the asterisk next to the dashed arrow).
[0056] The embodiments described herein also generally relate to various methods and treatments, including the use of the drugs (or drug compositions) described herein and the audio files described herein.
[0057] A method for inducing myelin growth in a patient may include administering the drug or drug composition described herein to the patient and having the patient hear or listen to the audio file described herein.
[0058] A method for regenerating the myelin sheath of a patient's nerves may include administering the medicine or pharmaceutical composition described herein to the patient and having the patient hear or listen to the audio file described herein.
[0059] A method for treating central hearing loss in a patient may include administering the drug or drug composition described herein to the patient and enabling the patient to hear or listen to the audio file described herein.
[0060] A method for treating a patient’s cocktail party defect may include administering the medicine or pharmaceutical composition described herein to the patient and having the patient hear or listen to the audio file described herein.
[0061] A method for treating a patient’s disease or medical condition may include administering the drug or pharmaceutical composition described herein to the patient and having the patient hear or listen to the audio file described herein. The disease or medical condition may include age-related hearing loss, autism, or hearing impairment caused by noise exposure or ear infections (e.g., early childhood ear infections).
[0062] In the methods described herein, administration of the drug or pharmaceutical composition to the patient may be performed before, simultaneously with, or after the patient hears or listens to an audio file. Administration of the drug or pharmaceutical composition to the patient and having the patient hear or listen to an audio file may induce myelin sheath growth along one or more afferent fibers to the medial trapezius nucleus.
[0063] In addition to age-related hearing loss, the embodiments described herein can be used to treat autism and hearing loss caused by noise exposure or ear infections (such as early childhood ear infections).
[0064] In the case of autism, it is well known that individuals with autism dislike situations such as crowded bars and restaurants because they have difficulty keeping up with conversations when background noise is present. The same demyelination observed in autistic mice (Fragile X) is similar to the demyelination observed in older gerbils described in this paper. This change may be the cause of the cocktail party deficit in autistic hearing individuals. The embodiments described herein can be used to remyelinate these pathways in autistic hearing individuals, just as they are done in older adults or the elderly population, and can be used to address the cocktail party deficit in autistic hearing individuals.
[0065] Many other listeners report difficulty hearing single sound sources in the presence of distracting background noise, yet these listeners have normal hearing thresholds, suggesting the problem lies in the brain rather than the ear. Some of these listeners have been exposed to loud sounds or noises, such as factory noise, throughout their lives. Animal models of these listeners show the same demyelination as aging or autistic animal models. The embodiments described herein can be used to remyelinate these pathways, as has been done in older adults or autistic listeners. Other listeners have experienced numerous ear infections during childhood. This coincides with the period when sound localization circuits calibrate. Ear infections cause mucus buildup in the middle ear, making sounds entering the ear muffled, as if there were earplugs. If an individual frequently experiences a "plugging sensation" or mucus in their ears for a significant portion of their life before age 2 (for example, some children experience this for about 50% of the time), the sound cues used to calibrate neural circuits constantly change and therefore cannot be calibrated. These listeners suffer from impaired cocktail party performance throughout their lives, which has been untreatable until now. The embodiments described herein can be used to treat early childhood ear infections.
[0066] Because chronic ear infections (especially in childhood) can lead to cocktail party defects due to mucus acting as an earplug, altering the loudness of sounds received in the infected ear, chronic ear infections can hinder the normal development of the sound localization pathway. The examples described herein can be used to treat early-onset chronic ear infections in children.
[0067] In other words, the embodiments described herein can be used to treat any suitable condition in which a listener reports a cocktail party defect, but has normal hearing at the ear level (i.e., they do not need hearing aids). These conditions baffle audiologists and otolaryngologists (ENTs), and there is currently no cure.
[0068] The following examples are provided to provide a complete disclosure and description of how aspects of this disclosure can be prepared and used by those skilled in the art, and are not intended to limit the scope of aspects of this disclosure. Efforts have been made to ensure accuracy regarding the quantities used (e.g., amounts, dimensions, etc.), but some experimental errors and deviations should be taken into account.
[0069] Example
[0070] Overview
[0071] The same brain circuitry responsible for sound localization plays a crucial role in helping individuals perform well in situations like cocktail parties (or acoustically busy environments with lots of background noise, such as restaurants, bars, airports, and cafeterias). Humans with normal hearing can localize sounds to a spatial degree of 5 degrees or better, meaning that in a cocktail party setting, as long as the interfering sound is at least 5 degrees away from the sound of interest, a person with normal hearing can distinguish any interfering sound from the sound of interest. As people age, sound localization ability and spatial accuracy decline, potentially limiting older adults to, for example, 25, 45, or 90 degrees. As a result, interfering noise from, for example, the next restaurant table, falls into the same spatial channel, making it impossible to distinguish. Approximately 50% of older adults complain of this deficiency and experience impaired performance in such cocktail party situations. Furthermore, individuals with autism have the same problem, as do people with several other hearing conditions (such as chronic childhood ear infections, multiple sclerosis), or some implant users.
[0072] The inventors investigated the underlying brain circuitry for this problem and identified a subcellular mechanism of age-related changes as demyelination in the afferent fibers of the vocalization pathway, particularly those leading to the medial trapezius nucleus. This demyelination results in less precise temporal transmission of neural activity, leading to temporally “loose,” imprecise localization and cocktail party deficits. The inventors tested whether demyelination in individual animals (Mongolian gerbils) could be reversed. A group of gerbils aged 2.5 years and older (equivalent to 70 to 80 years old in humans) were tested for vocalization deficits and cocktail party performance. The animals were then treated with clomastine fumarate and a control for one month. The carrier (control) was saline solution containing dimethyl sulfoxide (DMSO), as clomastine is dissolved in DMSO and then diluted with saline solution in the experiment. Some animals were also exposed to one hour of vocal files daily for one month. Thus, there were four study groups (carrier, carrier plus vocalization, clomastine (with carrier), and clomastine (with carrier) plus vocalization). Of the four groups, the group receiving clomastine plus sound showed significant improvements in myelination (anatomical), auditory brainstem response (physiological), and sound localization (behavioral).
[0073] Only the combination of sound and medication had this effect, while it was not observed in the combination of medication alone or in any other group. This is significant from a scientific point of view because brain pathways used in a meaningful and relevant manner are improved.
[0074] A. Introduction
[0075] A.1. Central hearing loss leads to hearing loss in typical acoustic environments.
[0076] Several mechanisms contribute to age-related hearing loss, the most well-known being the progressive death of inner ear hair cells. However, there are other core components that are poorly understood and for which no treatments are currently available. These core components, termed "central hearing loss," are not related to hair cell death, and patients affected by central hearing loss may have completely or largely normal hearing thresholds; in other words, audibility and sound detection are not problems. Central hearing loss is characterized by an inability to understand conversations in everyday situations, such as busy restaurants, public places, and most indoor spaces. Central hearing loss can affect up to 50% of the elderly population. Almost all listening scenarios are characterized by multiple simultaneously active sound sources, echoes, and reverberation, while listeners typically attempt to focus their attention on a single sound source. The inventors have demonstrated that age-related changes in the sound localization pathway in the auditory brainstem play a significant role in this type of central hearing loss. The inventors have also identified subcellular changes in this circuit that lead to less precise sound localization and reduced accuracy in spatial resolution between multiple simultaneous sounds. The inventors have discovered a novel method to reverse these age-related changes and partially restore spatial hearing. The following sections describe the scientific premises of the sound localization pathways involved in the cocktail party defect.
[0077] A.2. Sound localization pathway in the brainstem
[0078] The classic acoustic localization circuit in the brainstem is the lowest level circuit in the ascending pathway, where binaural localization cues are first encoded (see...). Figure 1A ).
[0079] For the purposes of this discussion, the inventors considered the primary sound localization nuclei, namely the medial superior olivary nucleus (MSO) and the lateral superior olivary nucleus (LSO). Both nuclei originate from the inner rhomboid nucleus (MNTB, solid arrow). Figure 1AThe sound localization process receives rapid and timely inhibition. During sound localization, sounds originating from different locations in space are distinguished based on differences in arrival time or intensity levels between the ears (i.e., interaural time difference (ITD) and interaural intensity difference (ILD)), which systematically vary with the location of the horizontal sound source. These cues are encoded by a sound localization loop to localize the sound and simultaneously perform initial separation of different sound streams based on location. The sound localization process relies on precise temporal integration of inputs from both ears because the interaural differences to be analyzed can be very small. For MSO, rapid and timely inhibition is considered a factor in ITD encoding and therefore localizing low frequencies. In typical natural listening conditions, a typical ITD is only on the order of tens to hundreds of microseconds, thus one to two orders of magnitude shorter than the duration of a typical action potential. On the other hand, localizing high frequencies via ILD has also proven to be highly sensitive to time shifts of only tens of microseconds (µs) between inhibitory and excitatory inputs. In fact, LSO neurons detect overlap of excitatory and inhibitory inputs from both ears within a window of <1 ms, thus even the processing of ILD is temporally constrained.
[0080] Due to these acoustic physical constraints, neurons in the sound localization circuit possess several subcellular specializations to enable the analysis of these ITDs and IIDs with the necessary temporal precision. Perhaps the most extreme example of this adaptation exists in the MNTB's ingress and egress pathways. This nucleus facilitates timely neural inhibition of the sound localization process. The pathway includes the ventral cochlear nucleus (VCN) ( Figure 1A The cochlear nucleus (as shown in the diagram) receives highly myelinated excitatory input to the contralateral MNTB. The MNTB in the trapezoidal body is primarily composed of neurons. The neurons in the MNTB that receive this input are glycemic, and these neurons send inhibitory outputs to several nuclei in the auditory brainstem, including the primary sound localization nuclei LSO and MSO (…). Figure 1A Some of the extreme adaptations made in this pathway for time precision include the Held calyx (a giant synapse that directly governs the MNTB chief cell body), the electrically compact design of the MNTB chief cell, small dendrites, the aforementioned high level of myelination of afferent fibers, and multiple subcellular and ion channel adaptations for rapid and precise firing.
[0081] A.3. Age-related changes in the ascending auditory pathway
[0082] Because of the extremely high demands on temporal precision in the sound localization circuit, even small age-related changes in the amplitude and / or dynamics of excitatory and / or inhibitory inputs to the MSO and LSO can significantly impact the encoding of ITD and ILD, thereby affecting overall binaural hearing. Consistent with this notion, substantial evidence suggests that temporal processing ability and neural synchronization decline with age, and this decline can lead to a reduced ability to separate multiple sounds. This age-related decline in temporal processing is not limited to humans; it appears to be a universal mammalian phenomenon. This is particularly true for the glycinergic inhibition provided by the MNTB, as these neurons appear to have the most extreme adaptation to temporal precision (see above). Furthermore, the MNTB projects glycinergic inhibition not only to the LSO and MSO but also to several other nuclei, directly or indirectly controlling the firing in most auditory brainstem nuclei. Figure 1A (Arrows not shown in the image). Overall, the MNTB is located at the center of one of the most precisely timed neural networks in the entire brain and can be considered the master switch for precise timing inhibition in the auditory system. A primary scientific premise is that age-related changes in subcellular structures impair the temporal accuracy of input to the sound localization pathway, particularly inhibitory inputs originating from the MNTB. This, in turn, leads to impaired sound localization and cocktail party performance in affected listeners or animal models.
[0083] A.4. Changes in myelination lead to central hearing loss.
[0084] One model separately calculated the effect of axonal demyelination in this circuit and concluded that the degree of demyelination observed in the experiments also led to a significant decrease in sound localization performance. Several studies provide evidence that reduced peripheral activity may lead to demyelination of cochlear nucleus axons and may reduce the total number of large-diameter axons; in adult rodents, after 10 days of ear blockage, the number of large-diameter axons was reduced, and the remaining axons had significantly thinner myelin sheaths compared to controls. Activity-dependent myelin plasticity has been reported in different systems beyond the auditory brainstem, and studies generally suggest that the release of glutamate or ATP from electrically active axons induces depolarization of oligodendrocytes, which subsequently differentiate and ultimately increase myelination of active axons—a pattern consistent with what has been observed here.
[0085] The inventors' experimental design focused on the auditory brainstem, but also carefully controlled for other possible mechanisms of age-related hearing loss. Briefly, histological examination of the cochlea was performed to control for hair cell death and synaptic lesions; auditory brainstem response (ABR) recording was also conducted, and wave IV corresponding to the physiological responses from the nerve to the auditory region of the midbrain, as well as the binaural interaction component (BIC), a measure of the binaural response in the sound localization pathway, were assessed. The state of myelination in the MNTB afferent fibers was also assessed microscopically, and the state of glycine receptors was assessed using RNAscope. In some experiments, distortion product otoacoustic emissions (DPOAE) recording was performed to further assess the physiological state of the cochlea (and the potential level of hair cell death).
[0086] A.5. Experimental isolation and reversal of aging effects
[0087] In some embodiments, the study focuses on the role of the sound localization loop in age-related central hearing loss, particularly the afferent axon to the MNTB (asterisk next to the dashed arrow). Figure 1A The role of age-related changes in myelination of axons. The myelin layer in these highly myelinated axons decreases with age, leading to reduced timing accuracy of action potential propagation, which in turn results in a worsening of the timing of glycineric inhibition derived from the MNTB pathway, and reduced accuracy of sound localization in affected human individuals and animal models. The inventors experimentally impaired myelination in the MNTB pathway in young animals using pharmacological methods to mimic the age-related changes observed in older animals. This allowed for the study of the effects of these changes in isolation. More importantly, the inventors (partially) reversed these changes in older animals using a combination of pharmacological and auditory stimulation. The pharmacological intervention used included clomastine fumarate (clomastine), a drug approved by the FDA for nearly 50 years and proven completely safe for human individuals. Therefore, this approach could potentially be converted into a treatment for human individuals with central hearing loss in a relatively short time, making it a first-line treatment option for central hearing loss.
[0088] Figure 1BThis paper provides a method for measuring PPI in gerbils, using a modified version of the procedure described by NT Greene et al. in “Spatial hearing ability of the pigmented Guinea pig (Cavia porcellus): Minimum audible angle and spatial release from masking in azimuth,” Hearing. Res. 365, 62-76 (2018) and S. Poleg et al. in “Age-related myelin deficits in the auditorybrain stem contribute to cocktail-party deficits,” bioRxiv 2024.07.29.605710 (2024). The animals were forced to remain forward-facing in their cages, focusing on the center of the speaker's arc (left image). A series of acoustic stimuli are played from one speaker (speaker 1) in an array. At a certain moment, just before a loud startle sound is played, the same acoustic stimuli are played from another speaker (speaker 2) in the array. If the animal can localize this speaker exchange, it means that the startle response to the impending startle sound will be weaker, resulting in a higher PPI. Conversely, if the animal cannot localize the speaker exchange, it will be "startled" by the startle sound (startle speaker) and jump more frequently, resulting in a lower PPI. Figure 1B (The image on the right). Figure 1B The right image shows the typical acoustic localization ability of older and younger gerbils. Smaller numbers indicate a reduced ability to detect speaker switching.
[0089] B. Method
[0090] A primary hypothesis of this study is that age-related changes in the auditory brainstem prevent listeners from separating sound sources of interest from background noise, and that reversing these changes could improve this ability. To this end, the inventors manipulated myelination of the MNTB afferent fibers.
[0091] B.1 Methodological Considerations
[0092] B.1.1. Species
[0093] All research on aging has been conducted on Mongolian gerbils (Meriones unguiculatus). Gerbils are a commonly used model system for hearing research, and a large body of literature has been published on them. This species has excellent low-frequency hearing (similar to humans), and therefore well-developed brain regions that process low frequencies. Gerbils experience relatively little age-related hair cell loss, making them effective for studying central nervous system changes. For this study, "old" gerbils were at least 2 years old, roughly equivalent to a human 60 years or older. "Young" gerbils were between 3 and 6 months old, roughly equivalent to a human in their 20s. Old gerbils were not available for purchase and therefore had to be raised in a laboratory. Research on autism was conducted on mice, while research on early childhood hearing and noise exposure was conducted on guinea pigs and chinchillas.
[0094] B.1.2. Behavioral assessment using pre-pulse inhibition (PPI)
[0095] While behavioral training in gerbils is feasible, it is extremely time-consuming, requiring weeks to months to obtain data from the animals. Therefore, the inventors opted instead to use a startle response method for all behavioral measurements. This methodology follows the descriptions in the following literature: MD Sergison et al., “Pre-pulse inhibition of the acousticstartle response as a behavioral assay for sound localization abilities of the Mongolian gerbil,” *Journal of the Acoustic Society of America*, 151, A147-A147 (2022); NT Greene et al., *Hearing Research*, 365, 62-76 (2018); KLAnbuhl et al., “Early temporal asymmetrical hearing impairs behavioral and neural sensitivity to sound location,” *Journal of the Acoustic Society of America*, 143, 1720-1720 (2018); and S. Poleg et al., bioRxiv 2024.07.29.605710 (2024). In short, the principle is that all animals (and individual humans) are startled when a loud sound is unexpectedly played, and the degree of startle can be quantitatively measured using an accelerometer placed under the animal's restraint cage. In contrast, the startle response is (partially) suppressed whenever the animal receives a cue that a startle is about to occur.
[0096] The inventors utilized this naturally occurring reflex and its inhibition by playing a series of sound stimuli through a given array of speakers arranged in a horizontal array. Just before startling, the speakers to be played were swapped, so that the exact same sound was played at different azimuth positions. If the animal could localize this "speaker swap," it would experience less startle. The array had individual speakers positioned in 7.5-degree spatial increments, allowing sound localization accuracy to be measured in multiples of 7.5 degrees. Animals were restrained in a constant and repeatable position relative to the array using a restraint cage that did not allow them to turn their heads or bodies. Pre-pulse inhibition was calculated as (1 - startle during the test period / startle during the control period), so a value close to zero indicated no speaker swap was detected, while a positive value indicated a swap was detected. At the start of data collection for each animal, a startle threshold was determined, and all experiments were conducted at a level 20 dB above that threshold. All PPI tests were conducted in a soundproof chamber using calibrated speakers.
[0097] B.1.3. ABR Records
[0098] This technique has been used for decades, and a large body of literature explains the various waves. ABR has been used by both the Tollin and Klug laboratories, both of which have published numerous papers on this technique, and the methodology follows these papers. In rodents, wave I is generally considered to reflect activity in the auditory nerve, wave II in the cochlear nucleus, and wave III in the MNTB. Wave IV reflects the primary sound localization nuclei, LSO and MSO. In addition to unilateral ABR, the inventors also performed binaural stimulation and recorded binaural ABR. BIC was calculated by pointwise calculation of (left ear ABR + right ear ABR - binaural ABR). If (assuming) there is no binaural circuit in the auditory brainstem, then this formula should make BIC a zero-amplitude function. Any non-zero value is caused by the input binaural interaction. Although the auditory nerve, cochlear nucleus, and MNTB are unilateral, the LSO and MSO are the lowest-level binaural nuclei; therefore, the first amplitude of BIC represents the activity of these nuclei. ABR recordings were performed using a TDT RX6 and Medusa device, controlled by custom-written software. Gerbils were mildly anesthetized with ketamine-xylazine; although these recordings are practically non-invasive, the animals' movement around the sound chamber during the procedure prevented the recording of any useful data. For recording, five electrodes were placed: behind each ear, on the top of the head, at the back of the head as a reference, and at the base of the tail as ground. At least 500 repetitions were recorded for each stimulus type. All ABR recordings were performed in a soundproof chamber using calibrated speakers and instruments.
[0099] B.1.4. CARS Microscope
[0100] Coherent anti-Stokes Raman spectroscopy (CARS) is used as a method for imaging lipids, such as myelin. This methodology follows the descriptions in the following literature: E.A. McCullagh et al., “Coherent Anti-Stokes Raman Spectroscopy (CARS) Application for Imaging Myelination in Brain Slices,” J Vis Exp, doi: 10.3791 / 64013 (2022); A. Lucas et al., “Myelination Deficits in the Auditory Brainstem of a Mouse Model of Fragile X Syndrome,” Front Neuroscience 15, 772943 (2021); and S. Poleg et al., bioRxiv2024.07.29.605710 (2024).
[0101] The CARS laser is tuned to 792.2 nm (the resonance frequency of the CH2 bond, which is very common in lipids) to excite these molecular bonds. Since myelin represents the majority of lipids in brain slices, this technique is largely targeted at myelin. This method is a relatively simple and efficient way to image and analyze myelin without using antibodies or electron microscopy. Another advantage is that CARS can be used in combination with immunohistochemistry and confocal optical microscopy. The laser is connected to an Olympus FV1000 confocal microscope, and the CARS laser is recalibrated daily.
[0102] B.1.5. Clomastine fumarate
[0103] Clomastine was initially approved by the U.S. government in the late 1960s as a first-generation antihistamine. While it is still approved for this application (including over-the-counter use in some counties), its use is now rare. However, this drug also has a second independent effect, in which it supports oligodendrocytes through cholinergic signaling pathways. Myelin regeneration can restore conduction velocity and promote neurophysiological recovery, highlighting the therapeutic potential of myelin repair. Clomastine treatment in patients with multiple sclerosis can shorten the latency of sensory evoked potentials, suggesting promising early results. Furthermore, the new oligodendrocyte generation induced by clomastine is expected to have a durable effect, as mature oligodendrocytes have a very long lifespan and are very stable once they form a myelin sheath.
[0104] From an experimental standpoint, chlormastine can be dissolved in dimethyl sulfoxide (DMSO), and then the mixture can be diluted with physiological saline. Therefore, the control solution consists of DMSO mixed with physiological saline.
[0105] B.1.6 Lysophosphatidylcholine
[0106] Several experimental models exist to study the regenerative response following myelin injury or loss. One of the leading focal toxin models for demyelination is lyso, which is injected stereotactically to induce demyelination only within the injection area. The temporal characteristics of demyelination and subsequent myelin regeneration have been well characterized over the past fifty years. Maximum damage is observed approximately one week after injection. Subsequently, myelination resumes within about three weeks. Lyso is mixed with fluorescent dyes to control the injection site and extent according to established protocols.
[0107] B.2 Preliminary Data
[0108] B.2.1. Elderly listeners may experience difficulties at cocktail parties, and gerbils also exhibit this deficiency.
[0109] Many older hearing individuals experience difficulties in cocktail party situations, which can be assessed through subjective self-assessment and objective sound localization and hearing in noise studies. These deficits are also observed in Mongolian gerbils.
[0110] Figure 2A The results shown are from 40 human individuals who underwent a test of their ability to spatially separate speech from noise. The results confirm that, with increasing age, individuals require increasingly larger spatial angles to successfully separate the signal from background noise. Furthermore, this difficulty does not begin abruptly at a certain age, but rather appears to develop slowly throughout the lifespan.
[0111] Figure 2BEquivalent results from Mongolian gerbils are shown. In this case, the animals' ability to localize sounds was tested using startle response and pre-pulse inhibition, with results from older animals (hollow circles and rectangles) and results from younger animals (circles and rectangles filled with forward slashes " / "). The data indicate that older gerbils perform significantly worse than younger animals in the sound localization task. Overall, Figure 2A and 2B The data suggests that this reduced ability to locate sounds is not just a human phenomenon, but appears to be a standard characteristic of mammals.
[0112] B.2.2. Changes in ABR wave III are a comorbidity of localization deficits in both humans and gerbils.
[0113] ABR records were also performed on the same individual human listeners and the same individual gerbils mentioned above. Data showed that... Figures 3A-3C ABR (Auditory Brain Response) is a physiological assessment of the lower auditory brain. Waves in the ABR trace represent activity in certain auditory centers, and wave III corresponds to the MNTB in humans and rodents. Smaller wave III amplitudes indicate that the neurons producing the wave (primarily MNTB neurons) fire during a larger time window, and are therefore less precise. In humans, wave III is typically smaller in older listeners. Because this condition affects approximately 50% of the population (and therefore 50% are unaffected), it is reasonable to inquire whether wave III is particularly lower in humans who report cocktail party deficit. Figure 3B That's how it is in China, and that's also the reality.
[0114] like Figures 3A-3C The data shows that many elderly individuals ( Figure 3A and 3B ) and many old gerbils ( Figure 3C The amplitude of wave 3 in gerbils decreased. The BIC of gerbils also decreased. Figure 7 (See right figure). This reduction in BIC also occurred particularly in individuals who performed poorly on the sound localization task. Additionally, questionnaires were given to individuals to self-assess their sound localization abilities. Those who self-assessed their abilities poorly had lower wave 3 amplitudes (…). Figure 3B Data shows that both humans and gerbils perform poorly in sound localization tasks as they age. Here, with increasing age, humans require a greater spatial separation between speech and noise. Figure 3A The same applies to gerbils, except that they use a startle response, so the measurement is based on pre-pulse inhibition (PPI). Simply put, a larger number means better sound localization. Figure 3BOverall, the data suggest that ABR records and BIC can serve as biomarkers for assessing vocal localization deficits in human individuals and animal models.
[0115] B.2.3. Subcellular mechanisms of these defects in gerbils
[0116] Invasive testing can be performed on gerbils to determine the neural mechanisms underlying the observed vocalization deficits and ABR changes. One mechanism involves demyelination of afferent axons into the MNTB principal neurons. These fibers are highly aberrantly myelinated, propagating action potentials with high speed and timing precision. As mentioned above, even minor age-related changes in this pathway can have a major impact on vocalization accuracy.
[0117] Methods for measuring myelin formation in the animal brain include imaging brain tissue using CARS (Cardiac Artificial Intelligence System). This technique works by tuning a laser to the resonance frequency of the CH2 bonds, which are very common in lipids (myelin is a lipid). These vibrating CH2 bonds are then imaged, such as... Figure 3D As shown. For this method, the CARS laser is tuned to 792.2 nm to target the CH2 bond.
[0118] Figure 4 CARS imaging data from young and old gerbils are presented to assess myelination. Here, myelinated fiber bundles from the cochlear nucleus to the MNTB and ultimately terminating at the Held calyx are imaged. Figure 4 Axon diameter data is also shown. Figure 4 The data provided show that in older gerbils, the reduction in myelin formation of these fibers leads to a significant decrease in the total axon diameter, indicating that older gerbils have significantly thinner fibers.
[0119] B.2.4. Targeted demyelination of MNTB afferent fibers can reproduce age-related changes.
[0120] To further confirm the role of MNTB afferent fiber demyelination in cocktail party defects, the inventors reproduced the aforementioned demyelination in young gerbils with normal vocalization abilities. For this purpose, the inventors injected lysophosphatidylcholine stereotactically into the afferent fiber pathway of MNTB. Lysophosphatidylcholine damaged the myelin sheath in the injection area within approximately one week, after which myelination recovered within approximately three to four weeks.
[0121] Figures 5A-5DThe results of artificially damaging the same fiber bundles in young animals are shown. The inventors injected lysophosphatidylcholine (lyso), a detergent, directly into the fiber bundles (by drilling holes in the animal's skull and injecting under pressure using a glass pipette). This result replicated in young animals what was observed in older animals: myelin damage (1 week after injection) resulted in ABR performance similar to that in older gerbils. Furthermore, vocalization was also affected. After 3 weeks, the system recovered, and therefore physiological and behavioral measurements also recovered accordingly. In short, this method “ages young animals.”
[0122] Specifically Figure 5A Results from a group of animals were presented, who underwent PPI testing at 1.5 and 3 weeks post-injection after receiving the chemical. Consistent with the effects and recovery methods of lyso, PPI values decreased during demyelination (1.5 weeks), indicating impaired sound localization. Figure 5A And recovered in 3 weeks. Similarly, waves III and IV of the ABR, as well as the BIC, were damaged during the same period of impaired sound localization, and also recovered in about 3 weeks. Figure 5B In addition, animals injected with lyso were sacrificed one, two, and three weeks after injection, and myelination in the MNTB afferent pathway was imaged using CARS. Figure 5C and 5D Consistent with behavioral and physiological outcomes, myelin was damaged one week after injection and recovered by week 3. Figure 5C and 5D These data suggest that targeted damage to the myelin sheath in the MNTB afferent pathway can at least partially reproduce age-related changes observed in older animals, indicating that demyelination is not merely a universal aging phenomenon but is causally related to central hearing loss. All measurements and analyses were performed by blinded observers.
[0123] B.2.5. Clomastine combined with sound exposure can salvage damaged myelin in older animals.
[0124] The inventors also conducted experiments contrary to the above description. Clomastine fumarate stimulates oligodendrocyte production by antagonizing cholinergic signaling. The inventors designed a series of experiments, testing a group of aged gerbils for PPI and ABR, followed by daily administration of clomastine or a control solution for one month. Some of these animals were also subjected to daily sound exposure. Therefore, there were four study groups: control solution, control and sound exposure, clomastine solution, and clomastine and sound exposure.
[0125] Sound exposure involved playing sound for one hour in a specially designed circular cage that did not produce a sound shadow and allowed the animal free movement within the cage. The sound played included sound segments with rapidly changing temporal components, such as binaural beats, fast amplitude modulation (FAM), fast frequency modulation (FM), and other rapid transient components. After a one-month treatment period, the same animals were tested again for PPI and ABR, followed by anatomical analysis using CARS.
[0126] Figure 6 The results of this rescue experiment show that treatment with clomastine and sound together (rather than clomastine and sound alone) can salvage the acoustic localization ability of older gerbils to a surprisingly high degree. Figure 6 (See bottom right image). This method "makes older animals younger." The acoustic localization ability of older gerbils was tested (solid line), and they were then divided into four groups. The group receiving clomastine and combined acoustic therapy showed significant improvement in acoustic localization ability, while the other groups showed no change.
[0127] Figure 7 The ABR records from the control group (top panel) and the clomastine plus sound group (bottom panel, treatment group) are shown. During the 4-month testing period, wave III and BIC significantly worsened in the control group, while the same parameters improved in the treatment group. Figure 7 The data show that the same animals that showed improvement in PPI also exhibited improvements in unilateral ABR (left panel) and BIC (right panel). Note that in the control animals (black), unilateral wave III showed minimal wave III before treatment (solid line, top left). This wave completely disappeared during treatment, most likely due to the progression of natural aging (dashed line, top left). In the same animals, BIC also significantly worsened during the same period. In contrast, animals treated with clomastine / sound (bottom panel) showed improvements in wave III (dashed line shows a more pronounced wave III than solid line) and a significant improvement in the temporal characteristics of BIC (dashed line in the bottom left panel rises more significantly). Animals treated with clomastine alone and sound alone did not show any such significant improvements (data not shown).
[0128] Figure 8 CARS imaging from the control / silent group (top left) and the clomastine / voiced group (top right) is shown. Quantitative analysis of all CARS data from this experiment is also shown (bottom). Figure 8This suggests that the potential mechanism for this behavioral and physiological rescue may be partial myelin regeneration of the afferent MNTB fibers. The left panel (top left) shows the CARS of the MNTB afferent fiber bundles from animals in the control / voiceless group, while the right panel (top right) shows the fibers from animals in the clomastine / voice group. The bottom panel shows a quantitative analysis of all pilot data from this experiment, indicating a significant increase in axonal width in the treatment group (this improvement was not shown in the other two groups, and data are not presented). Overall, Figure 8 The results shown indicate that the combination therapy of chlormastine and sound partially restored myelin formation.
[0129] Overall, the data presented in this paper suggest that drugs or drug combinations (e.g., clomastine) and audio files (sounds) can at least partially rescue age-related demyelination observed in the MNTB afferent pathway, and that this myelination regeneration rescues ABR wave III and BIC, and that these rescues also significantly improve the sound localization ability of the treated animals.
[0130] Example List
[0131] This disclosure provides, in particular, the following embodiments, each of which may be considered to optionally include any alternative embodiments:
[0132] Example 1. A combination therapy comprising:
[0133] Drugs or drug compositions; and
[0134] Audio file.
[0135] Example 2. A combination therapy according to Example 1, wherein the combination therapy is used to induce myelin growth in the patient, induce myelin regeneration in the patient, treat the patient's central hearing loss, treat the patient's cocktail party defect, treat the patient's age-related hearing loss, treat the patient's autism, treat the patient's ear infection, or a combination thereof.
[0136] Example 3. A combination therapy according to any one of Examples 1 to 2, wherein the drug or drug composition comprises an antihistamine, a prescription therapy for the treatment of multiple sclerosis, a myelin regeneration therapy, or a combination thereof.
[0137] Example 4. A combination therapy according to any one of Examples 1 to 3, wherein:
[0138] The drug or drug composition comprises an antihistamine; and
[0139] The antihistamines mentioned therein include chlormastine, GSK239512, or a combination thereof.
[0140] Example 5. A combination therapy according to any one of Examples 1 to 4, wherein:
[0141] The drug or pharmaceutical composition comprises a prescription therapy, myelin regeneration therapy, or a combination thereof for the treatment of multiple sclerosis; and
[0142] The prescribed therapies for multiple sclerosis, the myelin regeneration therapies, or combinations thereof comprise evatinib; SAR442168 (a Bruton's tyrosine kinase inhibitor in a phase 2 clinical trial); masitinib; imatinib; isotetrast; BIIB033 (an antibody against leucine-rich repeat-containing immunoglobulin-like domain protein 1, i.e., an anti-LINGO-1 antibody); opinumab (an antibody against LINGO-1); elenumab; autologous hematopoietic stem cell transplantation (AHSCT); simvastatin; vitamin D3; biotin (e.g., MD1003, a high-dose biotin); lipoic acid; nanocrystalline gold; laquinemod; GNbAC1 mAb (a monoclonal antibody against a human endogenous retroviral envelope protein); IMU-838 (vedovudine calcium); erythropoietin α; pioglitazone; montelukast; hydroxychloroquine; losartan; SPARC1103 (a GABA-containing protein); B Retinyl receptor agonists); Amantadine; Modanafil; Methylphenidate; BX-1 (Drocannabinol); ADS-5102 (Amantadine extended-release); Abaclofen (the R enantiomer of baclofen); Insulin; Intranasal insulin; Addara; Addara extended-release; GSK239512 (an orally administered centrally penetrating antihistamine); Orellizumab; Quetiapine (e.g., quetiapine fumarate); Domperidone; Anti-Sema4D (e.g., humanized anti-Sema4D monoclonal antibody VX15 / 2503); IRX4204 (a retinoic acid receptor γ-ray agonist); (RXR-γ) agonists; κ opioid agonists (e.g., U-50488, CAS No.: 67198-13-4); sphingosine-1-phosphate (S1P) receptor modulators (e.g., fingolimod or simpomod; γ-secretase inhibitors (e.g., quercetin); teriflunomide; bexarotin; bardoxifen; phenytoin; amiloride; adrenocorticotropic hormone; fluoxetine; riluzole; or combinations thereof.
[0143] Example 6. A combination therapy according to any one of Examples 1 to 5, wherein the audio file contains fast transient, time-changing components or combinations thereof.
[0144] Example 7. The combination therapy according to Example 6, wherein the rapidly changing component in time includes binaural beats, amplitude modulation signals, frequency modulation signals, rapid tapping, or combinations thereof.
[0145] Example 8. A combination therapy according to any one of Examples 1 to 7, wherein the combination therapy induces myelin sheath growth along afferent fibers to the inner trapezius nucleus.
[0146] Example 9. A method for inducing myelin growth in a patient, the method comprising:
[0147] Administering the drug or drug composition to the patient; and
[0148] The patient can hear or listen to an audio file.
[0149] Example 10. A method for regenerating the myelin sheath of a patient's nerves, the method comprising:
[0150] Administering the drug or drug composition to the patient; and
[0151] The patient can hear or listen to an audio file.
[0152] Example 11. A method for treating central hearing loss in a patient, the method comprising:
[0153] Administering the drug or drug composition to the patient; and
[0154] The patient can hear or listen to an audio file.
[0155] Example 12. A method for treating a patient's cocktail party defect, the method comprising:
[0156] Administering the drug or drug composition to the patient; and
[0157] The patient is made to hear or listen to an audio file.
[0158] Example 13. A method for treating a patient's disease or medical condition, the method comprising:
[0159] Administering the drug or drug composition to the patient; and
[0160] The patient is made to hear or listen to an audio file.
[0161] Example 14. The method according to Example 13, wherein the disease or medical condition includes age-related hearing loss, autism, or ear infection.
[0162] Example 15. The method according to any of Examples 9 to 14, wherein the drug or drug composition comprises an antihistamine, a prescription therapy for treating multiple sclerosis, myelin regeneration therapy, or a combination thereof.
[0163] Example 16. The method according to any one of Examples 9 to 15, wherein:
[0164] The drug or drug composition comprises an antihistamine; and
[0165] The antihistamine includes chlormastine, GSK239512, or a combination thereof.
[0166] Example 17. The method according to any one of Examples 9 to 16, wherein:
[0167] The drug or pharmaceutical composition comprises a prescription therapy, myelin regeneration therapy, or a combination thereof for the treatment of multiple sclerosis; and
[0168] The prescribed therapies for multiple sclerosis, the myelin regeneration therapies, or combinations thereof comprise evatinib; SAR442168 (a Bruton's tyrosine kinase inhibitor in a phase 2 clinical trial); masitinib; imatinib; isotetrast; BIIB033 (an antibody against leucine-rich repeat-containing immunoglobulin-like domain protein 1, i.e., an anti-LINGO-1 antibody); opinumab (an antibody against LINGO-1); elenumab; autologous hematopoietic stem cell transplantation (AHSCT); simvastatin; vitamin D3; biotin (e.g., MD1003, a high-dose biotin); lipoic acid; nanocrystalline gold; laquinemod; GNbAC1 mAb (a monoclonal antibody against a human endogenous retroviral envelope protein); IMU-838 (vedovudine calcium); erythropoietin α; pioglitazone; montelukast; hydroxychloroquine; losartan; SPARC1103 (a GABA-containing protein); B Retinyl receptor agonists); Amantadine; Modanafil; Methylphenidate; BX-1 (Drocannabinol); ADS-5102 (Amantadine extended-release); Abaclofen (the R enantiomer of baclofen); Insulin; Intranasal insulin; Addara; Addara extended-release; GSK239512 (an orally administered centrally penetrating antihistamine); Orellizumab; Quetiapine (e.g., quetiapine fumarate); Domperidone; Anti-Sema4D (e.g., humanized anti-Sema4D monoclonal antibody VX15 / 2503); IRX4204 (a retinoic acid receptor γ-ray agonist); (RXR-γ) agonists; κ opioid agonists (e.g., U-50488, CAS No.: 67198-13-4); sphingosine-1-phosphate (S1P) receptor modulators (e.g., fingolimod or simpomod; γ-secretase inhibitors (e.g., quercetin); teriflunomide; bexarotin; bardoxifen; phenytoin; amiloride; adrenocorticotropic hormone; fluoxetine; riluzole; or combinations thereof.
[0169] Example 18. The method according to any one of Examples 9 to 17, wherein the audio file contains fast transient, temporally rapidly changing components or combinations thereof.
[0170] Example 19. According to the method of Example 18, the rapidly changing component in time includes binaural beats, amplitude modulation signals, frequency modulation signals, rapid tapping, or combinations thereof.
[0171] Example 20. The method according to any one of Examples 9 to 19, wherein the method induces myelin sheath growth along the afferent fibers to the inner rhomboid nucleus.
[0172] Example 21. A combination therapy for stimulating myelin regeneration of neurons (e.g., neuronal axons) in patients with hearing loss, comprising:
[0173] A drug or pharmaceutical composition comprising an antihistamine, myelin regeneration therapy, a prescription therapy for the treatment of multiple sclerosis, or a combination thereof; and
[0174] An audio file configured to promote myelin regeneration of neurons after administration of the drug or drug composition.
[0175] Example 22. The combination therapy according to Example 21, wherein the hearing loss includes central hearing loss, cocktail party defect, age-related hearing loss, hearing loss due to ear infection, or a combination thereof.
[0176] Example 23. A combination therapy according to any of Examples 21 to 22, wherein: the drug or drug composition comprises the antihistamine; and the antihistamine comprises chlormastine, GSK239512, or a combination thereof.
[0177] Example 24. A combination therapy according to any one of Examples 21 to 23, wherein:
[0178] The drug or pharmaceutical composition comprises the myelin regeneration therapy, the prescription therapy for treating multiple sclerosis, or a combination thereof; and
[0179] The myelin regeneration therapy, the prescription therapy for the treatment of multiple sclerosis, or combinations thereof comprise evatinib; SAR442168; masatotinib; imatinib; isotetrast; BIIB033; opinumab; elenumab; AHSCT; simvastatin; vitamin D3; biotin; alpha-lipoic acid; nanocrystalline gold; laquimod; GNbAC1 mAb; IMU-838; erythropoietin alpha; pioglitazone; montelukast; hydroxychloroquine; losartan; SPARC1103; amantadine; modanafil; methylphenidate; BX-1; ADS-5102; abaclofen; insulin; intranasal insulin; addera; addera extended-release; GSK239512; ozoglucon; quetiapine; domperidone; anti-signalingin 4D; IRX4204; κ opioid agonist; sphingosine-1-phosphate (S1P) receptor modulator; γ-secretase inhibitor; teriflunomide; bexarotin; badoxifene; phenytoin; amiloride; adrenocorticotropic hormone; fluoxetine; riluzole; or combinations thereof.
[0180] Example 25. A combination therapy according to any of Examples 21 to 24, wherein the audio file contains fast transient, temporally rapidly changing components or combinations thereof.
[0181] Example 26. The combination therapy according to Example 25, wherein the rapidly changing component in time includes binaural beats, amplitude modulation signals, frequency modulation signals, rapid tapping, or combinations thereof.
[0182] Example 27. A combination therapy according to any of Examples 25 to 26, wherein the rapid transient has a frequency in the range of about 100 Hz to about 800 Hz, for example, about 200 Hz to about 600 Hz.
[0183] Example 28. A combination therapy according to any of Examples 21 to 27, wherein the combination therapy induces myelin sheath growth along afferent fibers to the inner trapezius nucleus.
[0184] Example 29. A method for stimulating myelin regeneration in neurons (e.g., neuronal axons) of a patient with hearing loss, the method comprising:
[0185] Administering a drug or pharmaceutical composition to the patient, the drug or pharmaceutical composition comprising an antihistamine, myelin regeneration therapy, a prescription therapy for the treatment of multiple sclerosis, or a combination thereof; and
[0186] The patient is made to hear or listen to an audio file configured to promote myelin regeneration of the neurons after administration of the drug or drug composition.
[0187] Example 30. The method according to Example 29, wherein the hearing loss includes central hearing loss, cocktail party defect, age-related hearing loss, hearing loss due to noise exposure, hearing loss due to ear infection, or a combination thereof.
[0188] Example 31. The method according to any of Examples 29 to 30, wherein: the drug or drug composition comprises the antihistamine; and the antihistamine comprises chlormastine, GSK239512 or a combination thereof.
[0189] Example 32. The method according to any one of Examples 29 to 31, wherein:
[0190] The drug or pharmaceutical composition comprises the myelin regeneration therapy, the prescription therapy for treating multiple sclerosis, or a combination thereof; and
[0191] The myelin regeneration therapy, the prescription therapy for the treatment of multiple sclerosis, or combinations thereof comprise evatinib; SAR442168; masatotinib; imatinib; isotetrast; BIIB033; opinumab; elenumab; AHSCT; simvastatin; vitamin D3; biotin; alpha-lipoic acid; nanocrystalline gold; laquimod; GNbAC1 mAb; IMU-838; erythropoietin alpha; pioglitazone; montelukast; hydroxychloroquine; losartan; SPARC1103; amantadine; modanafil; methylphenidate; BX-1; ADS-5102; abaclofen; insulin; intranasal insulin; addera; addera extended-release; GSK239512; ozoglucon; quetiapine; domperidone; anti-signalingin 4D; IRX4204; κ opioid agonist; sphingosine-1-phosphate (S1P) receptor modulator; γ-secretase inhibitor; teriflunomide; bexarotin; badoxifene; phenytoin; amiloride; adrenocorticotropic hormone; fluoxetine; riluzole; or combinations thereof.
[0192] Example 33. The method according to any of Examples 29 to 32, wherein the audio file contains fast transient, temporally rapidly changing components or combinations thereof.
[0193] Example 34. According to the method of Example 33, the rapidly changing component in time includes binaural beats, amplitude modulation signals, frequency modulation signals, rapid tapping, or combinations thereof.
[0194] Example 35. The method according to any of Examples 33 or 34, wherein the fast transient has a frequency in the range of about 100 Hz to about 800 Hz, for example, about 200 Hz to about 600 Hz.
[0195] Example 36. The method according to any one of Examples 29 to 35, wherein the method induces myelin sheath growth along afferent fibers to the inner rhomboid nucleus.
[0196] Example 37. A combination therapy for growing myelin sheaths on neurons (e.g., neuronal axons) of a patient with hearing loss, comprising:
[0197] A drug or pharmaceutical composition comprising an antihistamine; and
[0198] An audio file configured to promote myelin growth on neurons after administration of the drug or drug composition.
[0199] Example 38. A combination therapy according to Example 37, wherein the antihistamine comprises chlormastine, GSK239512, or a combination thereof.
[0200] Example 39. A combination therapy according to any of Examples 37 to 38, wherein the hearing loss includes central hearing loss, cocktail party defect, age-related hearing loss, hearing loss due to noise exposure, hearing loss due to ear infection, or a combination thereof.
[0201] Example 30. A combination therapy according to any of Examples 37 to 39, wherein the audio file contains fast transient, time-varying components or combinations thereof.
[0202] All documents described herein are incorporated herein by reference, including any priority documents and / or test procedures, provided they do not contradict this document. It will be apparent from the foregoing general description and specific embodiments that, although the forms of the embodiments have been illustrated and described, various modifications may be made without departing from the spirit and scope of this disclosure. Therefore, it is not intended to limit this disclosure. Similarly, the term “comprising” is considered synonymous with the term “including.” Likewise, whenever the transitional phrase “comprising” precedes a composition, element, group of elements, or method, it should be understood that we also contemplate the same composition, method, or group of elements preceding the description of the composition, element, plurality of elements, or method with the transitional phrase “substantially constitutes…,” “consisting of…,” “selected from the group of…,” or “is,” and vice versa, for example, the terms “comprising,” “substantially constitutes…,” “consisting of…” also include the product of the combination of elements listed after the term.
[0203] In the foregoing, reference has been made to embodiments of this disclosure. However, it should be understood that this disclosure is not limited to the specific embodiments described. In fact, any combination of the following features and elements (whether or not related to different embodiments) can be used to implement and practice this disclosure. Furthermore, while embodiments of this disclosure may achieve advantages over other possible solutions and / or over the prior art, whether a particular advantage is achieved by a given embodiment does not limit this disclosure. Therefore, the foregoing aspects, features, embodiments, and advantages are illustrative only and should not be considered elements or limitations of the appended claims unless expressly stated in the claims. Similarly, references to “this disclosure” should not be construed as a general expression of any inventive subject matter disclosed herein and should not be considered elements or limitations of the appended claims unless expressly stated in the claims.
[0204] For the purposes of this disclosure, and unless otherwise stated, all numerical values in the specific embodiments and claims herein are modified with "about" or "approximately" indicating values, and take into account experimental errors and variations as would be expected by one of ordinary skill in the art. For brevity, only certain ranges are explicitly disclosed herein. However, a range beginning with any lower limit may be combined with any upper limit to enumerate ranges not explicitly enumerated, and a range beginning with any lower limit may be combined with any other lower limit to enumerate ranges not explicitly enumerated, and in the same manner, a range beginning with any upper limit may be combined with any other upper limit to enumerate ranges not explicitly enumerated. For example, a statement of numerical ranges 1 to 5 includes subranges 1 to 4, 1.5 to 4.5, 1 to 2, and other subranges. As another example, a statement of numerical ranges 1 to 5, such as 2 to 4, includes subranges 1 to 4 and 2 to 5, and other subranges. Additionally, although not explicitly enumerated, a range includes each point or individual value between its endpoints. For example, a description of the numerical range 1 to 5 includes the numbers 1, 1.5, 2, 2.75, 3, 3.80, 4, 5, and other numbers. Therefore, each point or individual value can serve as its own lower or upper bound, and can be combined with any other point or individual value or any other lower or upper bound to enumerate ranges that are not explicitly listed.
[0205] As used herein, the indefinite article “a” or “an” shall mean “at least one” unless otherwise stated or clearly indicated by the context. For example, embodiments containing “medicine” include embodiments containing one, two or more medicines, unless otherwise stated or clearly indicated by the context that only one medicine is included.
[0206] While the foregoing description pertains to embodiments of this disclosure, other and additional embodiments of this disclosure may be devised without departing from the basic scope of this disclosure, the scope of which is defined by the appended claims.
Claims
1. A combination therapy for stimulating remyelination of neurons in a patient having hearing loss, comprising: a drug or pharmaceutical composition comprising an antihistamine, a remyelination therapy, a prescribed therapy for treating multiple sclerosis, or a combination thereof; and an audio file configured to promote remyelination of neurons after administration of the drug or pharmaceutical composition.
2. The combination therapy of claim 1, wherein the hearing loss comprises central hearing loss, a cocktail party deficit, age-related hearing loss, hearing loss due to noise exposure, hearing loss due to an ear infection, or a combination thereof.
3. The combination therapy of claim 1, wherein: the drug or pharmaceutical composition comprises the antihistamine; and the antihistamine comprises clemastine, GSK239512, or a combination thereof.
4. The combination therapy of claim 1, wherein: the drug or pharmaceutical composition comprises the remyelination therapy, the prescribed therapy for treating multiple sclerosis, or a combination thereof; and the remyelination therapy, the prescribed therapy for treating multiple sclerosis, or a combination thereof comprises evobrutinib; SAR442168; masitinib; imatinib; ibudilast; BIIB033; opicinumab; elezanumab; AHSCT; simvastatin; vitamin D3; biotin; lipoic acid; nanocrystalline gold; laquinimod; GNbAC1 mAb; IMU-838; erythropoietin alpha; pioglitazone; montelukast; hydroxychloroquine; losartan; SPARC1103; amantadine; modanafil; methylphenidate; BX-1; ADS-5102; arbaclofen; insulin; intranasal insulin; Adderall; Adderall extended-release formulation; GSK239512; Ocrelizumab; Quetiapine; Domperidone; Antisemaphorin 4D; IRX4204; κ-opioid agonist; Sphingosine-1-phosphate (S1P) receptor modulator; Gamma-secretase inhibitor; Teriflunomide; Bexarotene; Bazedoxifene; Phenytoin; Amiloride; Adrenocorticotropic hormone; Fluoxetine; Riluzole; or combinations thereof.
5. The combination therapy of claim 1, wherein the audio file comprises components that are rapidly transient, rapidly changing in time, or a combination thereof.
6. The combination therapy of claim 5, wherein the rapidly changing component in time comprises binaural beats, amplitude modulation signals, frequency modulation signals, rapid tapping, or combinations thereof.
7. The combination therapy of claim 5, wherein the rapid transient has a frequency in the range of about 100 Hz to about 800 Hz.
8. The combination therapy of claim 1, wherein the combination therapy induces myelin sheath growth along afferent fibers to the inner trapezius nucleus.
9. A method for stimulating myelin regeneration in neurons of a patient with hearing loss, the method comprising: Administering a drug or pharmaceutical composition to the patient, the drug or pharmaceutical composition comprising an antihistamine, myelin regeneration therapy, a prescription therapy for the treatment of multiple sclerosis, or a combination thereof; and The patient is made to hear or listen to an audio file configured to promote myelin regeneration of the neurons after administration of the drug or drug composition.
10. The method of claim 9, wherein the hearing loss comprises central hearing loss, cocktail party defect, age-related hearing loss, hearing loss due to noise exposure, hearing loss due to ear infection, or a combination thereof.
11. The method of claim 9, wherein: The drug or pharmaceutical composition comprises the antihistamine; and The antihistamine includes chlormastine, GSK239512, or a combination thereof.
12. The method of claim 9, wherein: The drug or pharmaceutical composition comprises the myelin regeneration therapy, the prescription therapy for treating multiple sclerosis, or a combination thereof; and The myelin regeneration therapy, the prescription therapy for the treatment of multiple sclerosis, or combinations thereof comprise evatinib; SAR442168; masitinib; imatinib; isotetrast; BIIB033; opinumab; elenumab; AHSCT; simvastatin; vitamin D3; biotin; alpha-lipoic acid; nanocrystalline gold; laquimod; GNbAC1 mAb; IMU-838; erythropoietin alpha; pioglitazone; montelukast; hydroxychloroquine; losartan; SPARC1103; amantadine; modanafil; methylphenidate; BX-1; ADS-5102; abaclofen; insulin; intranasal insulin; addera; addera extended-release; GSK239512; ozoglucon; quetiapine; domperidone; anti-signalingin 4D; IRX4204; κ opioid agonist; sphingosine-1-phosphate (S1P) receptor modulator; γ-secretase inhibitor; teriflunomide; bexarotin; badoxifene; phenytoin; amiloride; adrenocorticotropic hormone; fluoxetine; riluzole; or combinations thereof.
13. The method of claim 9, wherein the audio file comprises components that are fast transients, rapidly changing over time, or a combination thereof.
14. The method of claim 13, wherein the rapidly changing component in time comprises binaural beats, amplitude modulation signals, frequency modulation signals, rapid tapping, or combinations thereof.
15. The method of claim 13, wherein the fast transient has a frequency in the range of about 100 Hz to about 800 Hz.
16. The method of claim 9, wherein the method induces myelin sheath growth along afferent fibers to the inner pituitary nucleus.
17. A combination therapy for growing myelin sheaths on neurons in a patient with hearing loss, comprising: Antihistamines; and An audio file configured to promote myelin growth on neurons after administration of the antihistamine.
18. The combination therapy of claim 17, wherein the antihistamine comprises chlormastine, GSK239512, or a combination thereof.
19. The combination therapy of claim 17, wherein the hearing loss comprises central hearing loss, cocktail party defect, age-related hearing loss, hearing loss due to noise exposure, hearing loss due to ear infection, or a combination thereof.
20. The combination therapy of claim 17, wherein the audio file comprises components that are rapidly transient, rapidly changing in time, or a combination thereof.
